CHRS (Coherus Oncology) YoY EBITDA Growth: 35.08% (As of Mar. 2026)


CHRS Coherus Oncology Inc CHRS
42 GF Score
Price $1.55
GF Value $0.77
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology YoY EBITDA Growth?

Coherus Oncology CHRS +5.82% 42 YoY EBITDA Growth is 35.08% as of Mar. 2026. GuruFocus rates CHRS with a GF Score™ of 42/100 and a GF Value™ of $0.77 (Significantly Overvalued). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Coherus Oncology's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 35.08%.

Coherus Oncology's EBITDA per Share for the three months ended in Mar. 2026 was $-0.25.

Coherus Oncology YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology YoY EBITDA Growth Chart

Coherus Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -280.61 4.72 37.42 15.49 16.54

Coherus Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.03 17.13 5.33 4.01 35.08
CHRS
42GF Score
Coherus Oncology Inc CHRS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coherus Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Coherus Oncology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-1.453--1.741)/ | -1.741 |
=16.54 %

Coherus Oncology's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.248--0.382)/ | -0.382 |
=35.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 35.08% mean?
Coherus Oncology (CHRS) has a YoY EBITDA Growth of 35.08% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Coherus Oncology and its competitors.
Is Coherus Oncology's YoY EBITDA Growth too high?
Coherus Oncology's current YoY EBITDA Growth is 35.08%. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's YoY EBITDA Growth compare to CNXU and LENZ?
Coherus Oncology's YoY EBITDA Growth of 35.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Coherus Oncology and its competitors. Coherus Oncology's current YoY EBITDA Growth is 35.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.77, compared to a current price of $1.55 — trading 100.6% above its estimated fair value. The current YoY EBITDA Growth is 35.08%. Coherus Oncology's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current YoY EBITDA Growth is 35.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (CHRS) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of $1.55 is trading 100.6% above its estimated GF Value™ of $0.77. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for CHRS:

  • YoY EBITDA Growth: 35.08%
  • GF Value™: $0.77 vs. price of $1.55 (100.6% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges 8C5:Germany
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score

Get the complete analysis for CHRS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$0.77
GF Value